

Mozobil® (plerixafor) – First-time authorized brand alternative

- On July 11, 2023, Fresenius Kabi launched an authorized brand alternative of Sanofi/Genzyme's <u>Mozobil (plerixafor)</u> subcutaneous solution.
- Mozobil is approved in combination with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.